These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9343254)

  • 1. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.
    Descamps D; Collin G; Letourneur F; Apetrei C; Damond F; Loussert-Ajaka I; Simon F; Saragosti S; Brun-Vézinet F
    J Virol; 1997 Nov; 71(11):8893-8. PubMed ID: 9343254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.
    Quiñones-Mateu ME; Albright JL; Mas A; Soriano V; Arts EJ
    J Virol; 1998 Nov; 72(11):9002-15. PubMed ID: 9765445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility.
    Apetrei C; Descamps D; Collin G; Loussert-Ajaka I; Damond F; Duca M; Simon F; Brun-Vézinet F
    J Virol; 1998 May; 72(5):3534-8. PubMed ID: 9557632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing.
    García-Lerma JG; Heneine W
    J Clin Virol; 2001 Jun; 21(3):197-212. PubMed ID: 11397656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate.
    Quiñones-Mateu ME; Soriano V; Domingo E; Menéndez-Arias L
    Virology; 1997 Sep; 236(2):364-73. PubMed ID: 9325244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.
    Vergne L; Peeters M; Mpoudi-Ngole E; Bourgeois A; Liegeois F; Toure-Kane C; Mboup S; Mulanga-Kabeya C; Saman E; Jourdan J; Reynes J; Delaporte E
    J Clin Microbiol; 2000 Nov; 38(11):3919-25. PubMed ID: 11060045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D.
    Cornelissen M; van den Burg R; Zorgdrager F; Lukashov V; Goudsmit J
    J Virol; 1997 Sep; 71(9):6348-58. PubMed ID: 9261352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced antiretroviral drug susceptibility among patients with primary HIV infection.
    Little SJ; Daar ES; D'Aquila RT; Keiser PH; Connick E; Whitcomb JM; Hellmann NS; Petropoulos CJ; Sutton L; Pitt JA; Rosenberg ES; Koup RA; Walker BD; Richman DD
    JAMA; 1999 Sep 22-29; 282(12):1142-9. PubMed ID: 10501117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
    Shafer RW; Eisen JA; Merigan TC; Katzenstein DA
    J Virol; 1997 Jul; 71(7):5441-8. PubMed ID: 9188616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
    Cabana M; Clotet B; Martínez MA
    J Med Virol; 1999 Dec; 59(4):480-90. PubMed ID: 10534730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug resistance in newly infected individuals.
    Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
    JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients.
    Birk M; Sönnerborg A
    AIDS; 1998 Dec; 12(18):2369-75. PubMed ID: 9875574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.
    Brandin E; Lindborg L; Gyllensten K; Broström C; Hagberg L; Gisslen M; Tuvesson B; Blaxhult A; Albert J
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):543-50. PubMed ID: 12908931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients.
    Agwale SM; Zeh C; Paxinos E; Odama L; Pienazek D; Wambebe C; Kalish ML; Ziermann R
    AIDS Res Hum Retroviruses; 2006 Jan; 22(1):22-6. PubMed ID: 16438641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.